Listen to this article
A Landmark Achievement in Funding
Viome Life Sciences, a company at the forefront of longevity and preventative healthcare, has announced the successful closure of its Series C funding round, amassing an impressive $86.5 million. This oversubscribed round underscores the robust investor confidence in Viome’s mission and approach.
The Vision Behind Viome
Based in Bellevue, Washington, Viome Life Sciences is dedicated to translating cutting-edge scientific advancements into actionable and individualized health solutions. Their focus is not just on prolonging life but enriching it, ensuring that individuals can thrive in health and vitality.
The Power of Personalization
Viome’s unique approach challenges the conventional one-size-fits-all diet. Instead, it leverages science to determine the optimal health outcome for each individual based on their unique human and microbial gene expressions. Current nutritional practices often overlook our biochemical individuality, leading to the onset and progression of various chronic diseases. Viome’s data-driven approach is tailored to each individual, ensuring that nutritional guidelines are personalized and effective.
A Fusion of RNA Technology and AI
Viome’s groundbreaking approach combines proprietary RNA sequencing methods with advanced AI technology. This synergy analyzes epigenetic biomarkers, offering robust health insights that significantly contribute to promoting a healthy lifespan. With this combination, Viome provides at-home tests and custom-made health products to cater to each individual’s precise nutritional needs.
Retail Expansion and New Offerings
The recent funding will bolster Viome’s research and development endeavors and facilitate its retail expansion. A testament to its growing popularity, Viome’s Gut Intelligence Test will now be available in 200 CVS locations nationwide, marking it as the first-ever gut test to be offered in the national retail chain both online and in-store.
Backing from Renowned Investors
Major investors in the Series C round include notable names like Khosla Ventures, Bold Capital, WRG Ventures, and several other existing and new contributors. Their collective support has elevated Viome’s total funding to $175 million.
A Commitment to Revolutionizing Healthcare
Viome’s founder and CEO, Naveen Jain, emphasized the company’s dedication to a proactive approach to healthcare. He highlighted the transformative shift Viome is pioneering by harnessing the power of food and nutrition. Jain envisions a world where healthcare is not just reactive but proactive, focusing on prevention and long-term care.
A Bright Horizon for Viome
With its recent funding and continued innovations, Viome Life Sciences is poised to lead the charge in redefining health, wellness, and longevity. The company’s commitment to bridging the gap between scientific breakthroughs and practical health solutions promises a brighter, healthier future for individuals worldwide.
Please email us your feedback and news tips at hello(at)techcompanynews.com
